Faron Pharmaceuticals Ltd. has entered into a secured debt agreement with IPF Partners, which includes the issuance of warrants to IPF. The Board of Directors of Faron has resolved upon a warrant program directed to IPF, with a maximum total of 600,000 warrants to be granted. Each warrant entitles its holder to subscribe for one new share in the Company. The subscription price per share will be based on the 30-day volume-weighted average price of an ordinary share of Faron on the Nasdaq Helsinki First North exchange. The warrants may be exercised for a period of seven years following the drawdown of each tranche under the Funding Agreement. Faron has issued 319,944 warrants to IPF in relation to the first tranche utilized. The subscription price per share for these warrants is EUR 3.126. The terms and conditions of the warrants can be found on the Company's website. Faron is a clinical stage biopharmaceutical company focused on developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of the immune system. The Company's pipeline includes treatments for oncology, organ damage, and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors. Traumakine is an investigational therapy for the treatment of acute respiratory distress syndrome (ARDS) and other conditions. Faron is based in Turku, Finland.